non-dialysis chronic kidney diseases
Conditions
Interventions
Group 1:Xuezhikang 0.6g bid
Group 2:Xuezhikang 0.6g bid and Ezetimibe 10mg qd
Group 3:Atorvastatin 20mg qn
Sponsors
Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Any of the following items shall be satisfied for more than 3 months: (1) abnormal blood: BUN and Cr.(2) urine: hematuria, proteinuria (3) renal imaging abnormalities (4) renal pathological changes (5) glomerular filtration rate 2.6 mmol/L or severe CKD and CKD combined with hypertension or diabetes mellitus had ldl-c > 1.8 mmol/L.
Exclusion criteria
Exclusion criteria: 1. Secondary causes of myopathy (including myositis and rhabdomyolysis) or elevated liver enzymes, such as physical exercise, drug action, liver disease, etc.; 2. Patients with persistent dialysis or eGFR < 30ml/min.1.73m2; 3. Patients who are contraindicated or allergic to the use of xuezhikang; 4. Pregnant and lactating patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C;TC;TG;HDL-C;CCr;BUN;CK;CKMB;ALT;AST;MACEs; | — |
Secondary
| Measure | Time frame |
|---|---|
| hsCRP;TGF-ß; | — |
Countries
China
Contacts
Public ContactQiang She
Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed